Lista de obras -

A Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS-986231 in Healthy Volunteers

article

A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents

scientific article published on 01 October 2018

A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation

artículo científico publicado en 2017

A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial

artículo científico publicado en 2020

A retrospective study of complications of therapeutic plasma exchange in myasthenia

artículo científico publicado en 2012

Adaptive immune response to therapy in hmgcr autoantibody myopathy

artículo científico publicado en 2015

Anti‐musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts ⬇️

artículo científico publicado el 1 de julio de 2011

Assessment of the effects of lacosamide on sleep parameters in healthy subjects

artículo científico publicado en 2014

B cells in the pathophysiology of myasthenia gravis

artículo científico publicado en 2017

B10 Cell Frequencies and Suppressive Capacity in Myasthenia Gravis Are Associated with Disease Severity

artículo científico publicado en 2017

Characterization of B cells in muscle-specific kinase antibody myasthenia gravis

artículo científico publicado en 2015

Circulating microRNA plasma profile in MuSK+ myasthenia gravis

scientific article published on 06 October 2018

Clinical outcome measures following plasma exchange for MG exacerbation

artículo científico publicado en 2019

Comparative effectiveness clinical trials to advance treatment of myasthenia gravis

artículo científico publicado en 2018

Construction and validation of the chronic acquired polyneuropathy patient-reported index (CAP-PRI): A disease-specific, health-related quality-of-life instrument

artículo científico publicado en 2015

Cost analysis of myasthenia gravis from a large U.S. insurance database ⬇️

artículo científico publicado el 1 de diciembre de 2011

Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis

artículo científico publicado en 2015

Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine

artículo científico publicado en 2015

Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis.

artículo científico publicado en 2016

Emerging subspecialties in neurology: Clinical development

artículo científico publicado en 2013

Establishment of normative ranges of the healthy human immune system with comprehensive polychromatic flow cytometry profiling

artículo científico publicado en 2019

First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers

artículo científico publicado en 2020

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic

scientific article published on 25 March 2020

Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial

scientific article published on 17 October 2019

Inhibition of the transcription factor ROR-γ reduces pathogenic Th17 cells in acetylcholine receptor antibody positive myasthenia gravis

scientific article published on 12 December 2019

International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r

artículo científico publicado en 2016

Marked clinical and jitter improvement after eculizumab in refractory myasthenia.

artículo científico publicado en 2017

Myasthenia gravis and Lambert-Eaton myasthenic syndrome

artículo científico publicado en 2014

Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures

artículo científico publicado en 2018

Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy

artículo científico publicado en 2014

Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications

artículo científico publicado en 2014

Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects

artículo científico publicado en 2016

Population Pharmacokinetics and Exploratory Exposure-Response Relationships of Diazepam in Children Treated for Status Epilepticus

scientific article published on 28 September 2018

Population Pharmacokinetics and Exploratory Pharmacodynamics of Lorazepam in Pediatric Status Epilepticus

artículo científico publicado en 2016

Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia

artículo científico publicado en 2017

Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment

artículo científico publicado en 2013

Recommendations for myasthenia gravis clinical trials

artículo científico publicado en 2012

Reliability of the triple-timed up-and-go test.

artículo científico publicado en 2017

Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: timing, characteristics, and clinical outcomes

artículo científico

Therapeutic Drug Monitoring, Electronic Health Records, and Pharmacokinetic Modeling to Evaluate Sirolimus Drug Exposure-Response Relationships in Renal Transplant Patients

artículo científico publicado en 2016

Therapeutic Index Estimation of Antiepileptic Drugs: A Systematic Literature Review Approach.

artículo científico publicado en 2016

Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US

Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis

artículo científico publicado en 2010

Use of Therapeutic Drug Monitoring, Electronic Health Record Data, and Pharmacokinetic Modeling to Determine the Therapeutic Index of Phenytoin and Lamotrigine.

artículo científico publicado en 2016

Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy: CAPPRI

Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia

scientific article published on 18 July 2019

Lista de obras de

A Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS-986231 in Healthy Volunteers

A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents

A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation

A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial

A retrospective study of complications of therapeutic plasma exchange in myasthenia

Adaptive immune response to therapy in hmgcr autoantibody myopathy

Anti‐musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts ⬇️

Assessment of the effects of lacosamide on sleep parameters in healthy subjects

B cells in the pathophysiology of myasthenia gravis

B10 Cell Frequencies and Suppressive Capacity in Myasthenia Gravis Are Associated with Disease Severity

Characterization of B cells in muscle-specific kinase antibody myasthenia gravis

Circulating microRNA plasma profile in MuSK+ myasthenia gravis

Clinical outcome measures following plasma exchange for MG exacerbation

Comparative effectiveness clinical trials to advance treatment of myasthenia gravis

Construction and validation of the chronic acquired polyneuropathy patient-reported index (CAP-PRI): A disease-specific, health-related quality-of-life instrument

Cost analysis of myasthenia gravis from a large U.S. insurance database ⬇️

Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis

Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine

Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis.

Emerging subspecialties in neurology: Clinical development

Establishment of normative ranges of the healthy human immune system with comprehensive polychromatic flow cytometry profiling

First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic

Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial

Inhibition of the transcription factor ROR-γ reduces pathogenic Th17 cells in acetylcholine receptor antibody positive myasthenia gravis

International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r

Marked clinical and jitter improvement after eculizumab in refractory myasthenia.

Myasthenia gravis and Lambert-Eaton myasthenic syndrome

Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures

Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy

Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications

Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects

Population Pharmacokinetics and Exploratory Exposure-Response Relationships of Diazepam in Children Treated for Status Epilepticus

Population Pharmacokinetics and Exploratory Pharmacodynamics of Lorazepam in Pediatric Status Epilepticus

Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia

Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment

Recommendations for myasthenia gravis clinical trials

Reliability of the triple-timed up-and-go test.

Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: timing, characteristics, and clinical outcomes

Therapeutic Drug Monitoring, Electronic Health Records, and Pharmacokinetic Modeling to Evaluate Sirolimus Drug Exposure-Response Relationships in Renal Transplant Patients

Therapeutic Index Estimation of Antiepileptic Drugs: A Systematic Literature Review Approach.

Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US

Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis

Use of Therapeutic Drug Monitoring, Electronic Health Record Data, and Pharmacokinetic Modeling to Determine the Therapeutic Index of Phenytoin and Lamotrigine.

Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy: CAPPRI

Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia